Dr. Xi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
14000 E Arapahoe Rd
Suite 160
Centennial, CO 80112Phone+1 303-805-7744Fax+1 720-851-4141
Summary
- Jing Xi, MD is an Oncologist with a subspecialty in Breast Cancer based in Centennial, CO. She completed her Hematology and Medical Oncology fellowship at Washington University/B-JH/SLCH Consortium from 2019 to 2022, during which time she also served as a Clinical Fellow at Barnes-Jewish Hospital. Dr. Xi is a highly published researcher, with notable papers in the Journal of the National Comprehensive Cancer Network, BMC Cancer, Current Oncology Reports, and Breast Cancer Research and Treatment. Her research primarily focuses on various approaches to breast cancer treatment and predictors of tumor progression.
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2019 - 2022
- Shanghai Medical UniversityClass of 2008
Certifications & Licensure
- CO State Medical License 2022 - 2025
- MO State Medical License 2016 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 52 citationsNeutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancerDilan A Patel, Jing Xi, Jingqin Luo, Bilal Hassan, Shana Thomas
Breast Cancer Research and Treatment. 2019-01-02 - 60 citationsRetrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer.Jing Xi, Aabha Oza, Shana Thomas, Foluso O. Ademuyiwa, Katherine N. Weilbaecher
Journal of the National Comprehensive Cancer Network. 2019-02-01 - 45 citationsClinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti
Journal of the National Comprehensive Cancer Network. 2021-03-24
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: